The antioncogenes, or tumor suppressor genes, as negative regulators of cell division, stand in contrast to oncogenes. For most human cancers, the more frequently mutated genes are the antioncogenes, the principal exception being the leukemias and lymphomas. Persons heterozygous for germ-line mutations in antioncogenes are strongly predisposed to one or more kinds of cancer, and most dominantly inherited cancer is attributable to such heterozygosity. Seven antioncogenes have been cloned through the study of these persons, and several others have been mapped. An eighth one was mapped and cloned through the investigation of tumors and is not yet known in hereditary form. Three dominantly inherited forms of cancer are not attributable to mutations in antioncogenes. The corresponding nonhe-
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Virtually every human cancer can occur in genetically predisposed individuals. The A simple explanation for this incomplete penetrance is that oncogenesis requires a somatic mutation in some target cell, an event that may never occur in some heterozygous carriers; two mutations, one germinal and one somatic, would be needed (1) . This hypothesis also relates the hereditary and nonhereditary forms of a cancer by a common mechanism; the same two mutations would operate in both, the first mutation being germinal in the former and somatic in the latter. In the hereditary case all of the somatic cells would carry a first "hit," whereas in the nonhereditary case only a clone of somatic cells would do so.
What might the targets of these two hits be? The simplest answer is the two copies of some autosomal gene; oncogenesis would be recessive at the cellular level in both the hereditary and nonhereditary cases (2, 3) . The presence of one normal (wild type) copy of the gene would interfere with oncogenesis, and the normal allele could therefore be considered as antioncogenic. Such (6, 7) . The use of syntenic polymorphic genetic markers (restriction fragment length polymorphisms, RFLPs) permitted demonstra- (8) and of the mechanisms predicted (4) for second events-namely, local mutation, deletion, chromosomal nondisjunction, and somatic recombination. Loss of heterozygosity of at least some syntenic markers is a feature of all of these mechanisms except the first. RFLPs were also used for the positional cloning of the RBI gene (9) (10) (11) 
Wilms Tumor
Wilms tumor was the second cancer for which a relationship between hereditary and nonhereditary forms was proposed (18) . This tumor occurs in =10 per 100,000 children. Here again the discovery of cases with constitutional deletions-at 11p13-pointed to the location of the putative WTI gene (19) and so to regional RFLPs that were used to find molecular mutations and deletions and to clone the gene (20, 21) . Patients with constitutional mutations or deletions of WTI appear not to be susceptible to other tumors. The gene's specificity fits well with the limitation of its expression to the genitourinary tract, the mesothelial lining of the body cavities, the spleen, and parts of the central nervous system, in contrast to RBI 's ubiquitous expression (reviewed in ref. 22 ). Genitourinary anomalies are common in children who are heterozygous for mutation or deletion of WTI, and some mutations produce the Denys-Drash syndrome, which is also predisposing to Wilms tumor.
Mice made heterozygous for a mutation of WTI do not develop Wilms tumor, again probably because, as for RBI mice, the target-cell population is too small (23) . Even in humans the penetrance of WTI mutations for Wilms tumor is lower than that of RBI for retinoblastoma. The homozygous mutant state is again lethal, at 13-15 days, with a failure of development of the metanephric kidney. Lethality is apparently attributable to widespread edema secondary to impaired development of the thoracic mesothelium, heart, and lungs. Like RBI, WTI is a developmentally lethal recessive gene that in the heterozygous mutant state predisposes its human host to cancer.
Wilms tumor differs from retinoblastoma in another important way. Whereas RBI appears to be the only gene whose mutations predispose to retinoblastoma, only about 10-20o of Wilms tumors can be attributed to mutation at WTI. A wellrecognized but rare dominantly heritable disorder, the Beckwith-Wiedemann syndrome (BWS), also predisposes to this tumor. The BWS gene has not been cloned, but clinical features suggest that BWS may not be an antioncogene. Infants with the syndrome are large at birth and exhibit features that suggest the posReview: Knudson sibility of heterozygosity for an overexpressing mutation of an oncogene.
BWS has been mapped by linkage analysis to chromosomal region ilp15, a considerable distance from WTI (24) . One gene in this region, that for insulin-like growth factor 2 (IGF2), is especially relevant because its product is a fetal growth factor, expressed strongly in fetal kidney and in Wilms tumor but not in the adult kidney. It is also an imprinted gene, the maternally derived allele being unexpressed. In BWS, and in some nonhereditary Wilms tumors, this imprinting is relaxed and both parental alleles are expressed, thereby presumably causing excessive fetal growth (25) (26) (27) Later it was found that TP53 is constitutionally mutant in most cases of LFS (29) , a dominantly inherited syndrome discovered through the study of familial rhabdomyosarcoma in children (30) . The families of these children proved to have a high incidence of other cancers, including especially breast carcinoma, but also soft tissue sarcomas (including rhabdomyosarcoma), osteosarcoma, brain tumors, leukemia, adrenocortical carcinoma, and perhaps some other carcinomas. The breast cancers typically occur in subjects before the age of 50 years, even in their 20s. The incidence of LFS is probably 2-4 per 100,000 births, and the high mortality before the end ofthe age of reproduction assures that it is maintained in populations only by recurrent spontaneous germ-line mutations.
A remarkable feature of LFS is that some carcinomas are not typical. Thus, carcinoma of the colon and small-cell carcinoma of the lung, both with high incidence of somatic mutations of TP53, are not important tumors in LFS. Why does one carcinoma, that of the breast, but not two others, those of the colon and lung, develop frequently in LFS subjects? Perhaps there is a clue in a comparison of the tumors that typify the heterozygous carriers of RBI and TP53. In both instances sarcomas of soft tissues and bone are conspicuous among carriers in the first two decades of life. Mutations of both genes are common in nonhereditary tumors ofthese histologies; but they are also both common among cases of nonhereditary small-cell carcinoma of the lung, a tumor that is not typically found in constitutional heterozygotes for mutation at either gene. Interestingly, the sarcomas occur during a time of net growth in somatic tissues, which is accompanied by growth of tissue stem cells. In this respect these tissues partially resemble the growth of fetal retina and kidney, where clones of once-hit cells greatly magnify the number oftarget cells available for mutation or loss of the second allele of RBJ or WTI, respectively. Breast is another tissue that undergoes net growth in adolescence. On the other hand, colon and lung are typical renewal tissues; development of once-hit clones in a renewal tissue is uncommon unless there is some stimulus to stem cell proliferation, as happens in the colon with chronic ulcerative colitis, and, possibly, in the lung in response to cigarette smoking.
The TP53 gene, like RBI, can also influence passage through the G1 phase of the cell cycle (31) . Especially interesting is the observation that normal cells, but not those mutant at TP53, are arrested temporarily in G1 by ionizing radiation (32) . It is therefore something of a surprise that mice transgenic for expressing mutant p53 alleles (33) (36) raises the possibility that tumors themselves, at some point in their histories, elicit a host defense in the form of increased production of p53, which is inhibitory to tumor growth. Only then would mutation or loss of TP53 impart a selective advantage to a cell. Thus, mutation at RBI might initiate an osteosarcoma cell, but its malignancy would depend upon loss of normal p53 activity. In small-cell lung cancer, a tumor of a typical renewal tissue, yet another negative control might inhibit growth until it too is mutated. There seem to be three kinds of tissues: (i) embryonal tissues whose normal growth is unconditional once proliferation is initiated; (ii) "conditional tissues" like bone, whose growth can be induced as by hormones at puberty; and (iii) renewal tissues, which have a capacity for conditional response but in addition are programmed for daily replenishment (14) . TP53 plays an important role in these latter two tissue categories, but the second category is the principal target for oncogenesis in LFS.
Antioncogenes and Tumors of Neural and Neural Crest Origin
Neuroblastoma. In addition to RB1 there are several antioncogenes that predispose to tumors of neural origin with some specificity. Along with retinoblastoma and Wilms tumor, neuroblastoma was one of three embryonal tumors treated as models of hereditary cancer involving constitutional heterozygosity for a mutant gene that is also important in the nonhereditary form of the same tumor (37) . The tumors commonly show a deletion that includes all or part of chromosomal region lp36, so that site has been suspected as the locus of a NBI gene (38, 39) . However, familial neuroblastoma is rare and linkage analysis has not been conducted. Two case reports of neuroblastoma with constitutional aberrations of 1p36 enhance the candidacy of an antioncogene at this site (40, 41 it has not yet been cloned (54, 55) . A claim has been neurectoder made for another familial melanoma gene hereditary c( on chromosome arm lp (56) . Preneoplas-already bee: tic benign nevi usually precede the ap-gliomas, alti pearance of melanomas, suggesting one penetrance. somatic event producing the nevus, and quently seen still further events leading to malignancy. lignancy, an Nonhereditary melanomas often show tant cells has loss of heterozygosity for 9p markers and with progres even homozygous deletions at band 9p21 of chromoso (57) , indicating the importance of the ously as coI MLM antioncogene for both the heredi-remains to b tary and nonhereditary forms of mela-fected genei noma. The 9p2l site has been implicated mutant in h in other tumors, including brain tumors site is appan (58), some leukemias (59), and some lung gression, as i cancers (60) rmal tumors (PNETs). Two onditions, NF1 and LSF, have n observed to predispose to hough neither does so at high Mutations at TP53 are fren in gliomas of high-grade maid clonal expansion of p53 mus been observed in association ssion in glioma (66) . Deletions me 9p have been noted previmmon in glial tumors, and it )e determined whether the afis identical with the one that is ereditary melanoma. The 9p ently important in tumor prois one on chromosome 10q, an ;rsally affected chromosome in ignant glioblastoma (67) . Still, at no explanation for pedigrees ighly penetrant dominant ingliomas, even over three genexample, see ref. 68 ), which to initiating events in glioma ad to a new antioncogene. which usually occur in chil-:casionally found in patients sposing germ-line mutation in igene, as with TP53 or NFI. one condition has regularly iated with PNETs-namely, Irome, or basal cell nevus BCNS), whose gene has been linkage analysis to 9q31 (69) . mutation at the BCNS locus riably develop basal-cell carthe skin, and approximately e tumors reveal loss of hetfor 9q markers, suggesting e of an antioncogene on that al arm (70) . A few percentage with the syndrome develop Id =25% of nonhereditary tomas also reveal loss of hetfor 9q markers (70) . It is that syndrome subjects with in some cases received craradiation, which in turn innumbers of cutaneous basal mas, with a short latent peiting the induction of numer-I hits" that led to cancer (71 cell carcinoma (RCC). Curiously, the last two tumors are uncommon in the same family, although bilateral tumors are frequent at each site when they do occur (72) . The gene was localized by linkage analysis to chromosomal band 3p25 and recently cloned (73) . Its protein product appears to be a cell surface molecule involved in cell adhesion and signal transduction. It will be of interest to discover whether the protein interferes with the function of an oncogene that is involved in signal transduction. Examination of nonhereditary renal carcinomas reveals abnormality of VHL in a high percentage of cases, making it the principal RCC gene. Both of these nonhereditary tumors and the tumors found in the syndrome typically reveal mutation or loss of the second copy of the gene, as expected for an antioncogene. However, one family with high penetrance for RCC carried a constitutional translocation with one breakpoint at 3p14-21 far from the VHL gene (74) . It seems likely that 3p harbors a second RCC gene, although it is possible that the tumors in translocation patients have sustained 3p deletions that cause loss of the VHL gene. Phenotypically, the tumors in both inherited forms are of the common clear cell histology. In addition, there are nonclear cell tumors that do not show LOH for chromosome 3p markers, suggesting the existence of yet another renal cancer gene. Nonclear cell RCC is known in hereditary form in the Eker rat, and the gene has been localized to rat chromosome 10q, in a region that seems to be homologous in part with 16p in humans (75) . In neither humans nor rats do predisposed gene carriers develop Wilms tumor, nor do carriers of a Wilms tumor mutation develop RCC. Here again there is specificity for a developmental state in an organ, as with the adrenal medulla for neuroblastoma and pheochromocytoma.
Familial Adenomatous Polyposis and Colon Cancer. One of the best known hereditary conditions that predispose to a major cancer ofadults is familial adenomatous polyposis (FAP), which occurs in persons heterozygous for a mutation in the adenomatous polyposis coli (APC) gene. APC is located at chromosomal band 5q21 and has been cloned (76, 77) . Its protein product is located in the cytoplasm and has features suggesting potential for interaction with other proteins, perhaps the product of some oncogene. In typical FAP cases, the colonic mucosa is studded with hundreds or even thousands of benign adenomatous polyps. These polyps, which begin to appear even in the first decade of life, are clonal in origin. Polyps of this same type occur sporadically in normal individuals; cells of even very small polyps are mutated somatically at the APC locus (78) . It has been reported that many, conceivably even all, polyps have sustained mutations or loss of both copies of the APC gene (79, 80) .
The crypts of the colonic mucosa in FAP patients show a larger than normal proliferative compartment (81); in effect the APC mutation causes an expansion of the target cell compartment. This phenomenon is not clonal and appears to be a dominant effect of the constitutional mutation, even though some of the mutations involve total deletions of the gene. However, the mutations most often introduce termination codons that cause extreme truncation of the protein product, which can interact with the normal allele's product, interfering with the latter's function and causing the mutation to behave in a "dominant negative" manner, as with some mutations in TP53 (82) . It will be interesting to compare the phenotypic effects of null and truncating mutations.
Mutations at the APC gene in the mouse produce multiple intestinal neoplasia (Min)-i.e., polyps and carcinomas (83) (84) (85) . Multiple cell lineages in the tumors suggest that the mutation exerts its effect upon a pluripotent stem cell. Homozygotes for the mutation die during fetal life (85) , indicating that the gene has an important role in normal development, as is true also for RBI and WTI.
Even if mutation at the APC locus is a necessary condition for carcinoma of the colon, it does not suffice. Other genetic events are the rule for this tumor, the targets being the KRAS oncogene, the TP53 antioncogene (86) , and the DCC (Deleted in Colon Cancer) antioncogene (87) . KRAS mutations are featured in large polyps, where their incidence is -400o. They are rare in very small polyps, and their incidence in carcinomas is about the same as in large polyps. They seem not to be directly involved in malignant transformation ofthe latter. On the other hand, TP53 and DCC mutations occur uncommonly in polyps but in the majority of carcinomas. It has not been established whether there is a necessary sequence for mutation in these two genes.
The DCC gene was identified following LOH studies that showed frequent losses for markers on chromosome 18q (87 (88) , and one patient with a constitutional deletion of 18q, the arm that contains the DCC gene, developed a brain tumor (89) . Could it be that germ-line mutations of DCC would be associated with brain tumors rather than with colon cancer?
Another hereditary condition, known as the Lynch cancer family syndrome type 2, imparts susceptibility to numerous types of carcinoma, including that of the colon. A gene for it (there may be more than one), LCFS2, has recently been mapped to chromosome 2, a chromosome not previously implicated in colon carcinogenesis (90) (97, 98) , especially in small-cell lung cancer (SCLC), although, as noted previously, this cancer is not a characteristic feature of hereditary retinoblastoma or of the LFS. A third change, found almost universally in SCLC, and in a majority of cases of non-SCLC, is deletion of chromosome 3pl4-p21 (99, 100) . There is at least one lung cancer antioncogene (LCI) on chromosome 3p. SCLC is similar to colon cancer in that three different antioncogenes appear to be critical to both, with p53 being common to them. A difference is that none of the three lung cancer genes (RBI, TP53, or LC1) resembles APC by providing strongly predisposing germ-line mutations.
Prostate Cancer. The genetics of prostate cancer is poorly understood, but the analysis of familial cases has led to the conclusion that there is a dominantly inherited predisposing gene (101) . A possible clue to the location of such a gene has been provided by cytogenetic and loss of heterozygosity studies in tumors, which have revealed a few recurrent abnormalities. Deletion commonly occurs at 8p22, and was even homozygous in one case (102) . Deletion at 10q24 has been reported as the sole anomaly in some tumors and displayed clonal evolution in one patient (103) Table 2 ). The APC and NFI gene products appear to function in the cytoplasm, whereas the products of NF2, VHL, and DCC seem to be located at the cell membrane. If one assumes that positive and negative regulation occurs at all points in the signal transduction pathway, then it may be that the study of the control of oncogene activity could lead to identification of new inhibitory factors that would be candidates for antioncogenes.
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